- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04962620
Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital Endometriosis
July 15, 2021 updated by: NPO Petrovax
Multicenter Prospective Non-interventional Study of the Efficacy and Safety of Longidaze®, Vaginal and Rectal Suppositories, 3000 IU, for the Treatment of Patients With External Genital Endometriosis
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of external genital endometriosis .
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The aim of the study is to compare the outcomes of complex therapy in patients with external genital endometriosis who, in addition to hormonal therapy, were prescribed Longidaze®, vaginal and rectal suppositories, 3000 IU, with the outcomes of therapy in patients who received only hormonal therapy.
Study Type
Observational
Enrollment (Anticipated)
149
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation, 109388
- Federal State Autonomous Educational Institution of Higher Education "Peoples' Friendship University of Russia"
-
Moscow, Russian Federation, 119048
- Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation
-
-
Chelyabinsk Region
-
Chelyabinsk, Chelyabinsk Region, Russian Federation, 454048
- State budgetary healthcare institution "Chelyabinsk Regional Clinical Skin and Venereal Diseases Dispensary"
-
-
Leningrad Region
-
Saint Petersburg, Leningrad Region, Russian Federation, 199034
- Federal State Budgetary Scientific Institution "Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott "
-
-
Nizhny Novgorod Region
-
Nizhny Novgorod, Nizhny Novgorod Region, Russian Federation, 603140
- Private health care institution "Road clinical hospital at the station Nizhny Novgorod of the open joint stock company" Russian Railways "
-
-
Voronezh Region
-
Voronezh, Voronezh Region, Russian Federation, 394036
- Federal State Budgetary Educational Institution of Higher Education "Voronezh State Medical University named after N.N. Burdenko "of the Ministry of Health of the Russian Federation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients with a verified diagnosis of external genital endometriosis, who, as part of routine clinical practice, were prescribed monotherapy with per os dienogest or combined treatment with a combination of dienogest + vaginal and rectal suppositories Longidaze®, 3000 ME (hereinafter referred to as Longidaze® )
Description
Inclusion Criteria:
- Documented informed consent;
- Patients over 18 years of age with active menstrual function;
- Women with external genital endometriosis, confirmed morphologically and visually during laparoscopic or laparotomy surgery performed 10 years to 2 weeks prior to Day 0;
Patients in the framework of routine clinical practice in accordance with the instructions for use, prior to inclusion in the study, are assigned one of the following therapy regimens:
- monotherapy with dienogest 2 mg daily for at least 6 months per os
- complex treatment with dienogest 2 mg daily for at least 6 months per os in combination with vaginal and rectal suppositories Longidaze® 1 suppository 1 time every 2 days 10 suppositories, and then 1 suppository 1 time in 7 days 17 suppositories for another 120 days;
- Willingness to use barrier methods of contraception.
Exclusion Criteria:
- Women before menarche or after menopause
- Adenomyosis;
- Amenorrhea (more than 3 months in a row within 6 months before screening);
- Patients who are scheduled to undergo surgery for endometriosis during the study;
- Hormone therapy for endometriosis or the use of aromatase inhibitors within 16 weeks prior to Day 0;
- Daily use of pain relievers for 7 consecutive days or more due to any other reason other than endometriosis;
6. Participation in clinical trials less than 30 days before the screening visit and / or 5 drug half-lives, whichever is longer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Longidaze
75 patients receiving combination therapy: Longidaze + dienogest
|
Rectally or vaginally 1 suppository of Longidaze every 2 days.
The main course of treatment - 10 suppositories (for 30 days).
Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days.
Course of supportive treatment - 17 suppositories for another 120 days.
The patients took dienogest according to the instructions for use.
|
Control
74 patients receiving only Dienogest.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the severity of endometriosis-associated pelvic pain (Day 30)
Time Frame: Day 0, Day 30
|
Changes in the severity of endometriosis-associated pelvic pain by visual analogue scale (VAS) after 30 days from the baseline value in patients of the dienogest + Longidaze® combination therapy group compared with patients who received only dienogest.
The Visual Analogue Scale (VAS) is designed to measure pain intensity.
It is a continuous scale in the form of a horizontal line 10 cm (100 mm) long and located on it two extreme points: "no pain" and "the strongest pain you can imagine."
The patient is asked to place a line perpendicularly crossing the visual analogue scale at the point that corresponds to his pain intensity.
The ruler measures the distance (mm) between "no pain" and "the worst pain imaginable," providing a score range from 0 to 100.
A higher score indicates more pain intensity.
|
Day 0, Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the severity of endometriosis-associated pelvic pain (Days 90, 150, 180)
Time Frame: Day 0, Day 90, Day 150, Day 180
|
Changes in the severity of endometriosis-associated pelvic pain according to the VAS after 90, 150 and 180 days relative to the baseline value in patients of the dienogest + Longidaze® combination therapy group compared with patients who received only dienogest.
The Visual Analogue Scale (VAS) is designed to measure pain intensity.
It is a continuous scale in the form of a horizontal line 10 cm (100 mm) long and located on it two extreme points: "no pain" and "the strongest pain you can imagine."
The patient is asked to place a line perpendicularly crossing the visual analogue scale at the point that corresponds to his pain intensity.
The ruler measures the distance (mm) between "no pain" and "the worst pain imaginable," providing a score range from 0 to 100.
A higher score indicates more pain intensity.
|
Day 0, Day 90, Day 150, Day 180
|
Change in the Biberoglu and Berman scale
Time Frame: Day 0, Day 30, Day 90, Day 150, Day 180
|
Change in the Biberoglu and Berman scale after 30, 90, 150 and 180 days from the baseline value from the start of treatment in patients of the dienogest + Longidaze® combination therapy group compared with patients who received only dienogest.
The Biberoglu and Berman scale consists of five 4-point scales for assessing the severity of dysmenorrhea, dyspareunia and chronic pelvic pain not associated with menstruation, as well as the assessment of pain and static hyperalgesia during gynecological examination.
In each of the scales, 0 points - no symptom, 3 points - the most pronounced symptom.
The result is assessed by the sum of points for each symptom.
With a sum of points from 1 to 2, pelvic pain is considered mild, from 3 to 5 - moderate, from 6 to 10 - strong, from 11 to 15 - severe.
|
Day 0, Day 30, Day 90, Day 150, Day 180
|
Change in the score on the SF-36 quality of life questionnaire
Time Frame: Day 0, Day 30, Day 90, Day 150, Day 180
|
Change in the score on the SF-36 quality of life questionnaire after 30, 90, 150 and 180 days relative to the baseline value from the start of treatment in patients of the dienogest + Longidaze® combination therapy group compared with patients who received only dienogest.
|
Day 0, Day 30, Day 90, Day 150, Day 180
|
Change in the severity of uterine bleeding
Time Frame: Day 0, Day 30, Day 90, Day 150, Day 180
|
Change in the severity of uterine bleeding after 30, 90, 150 and 180 days from the start of treatment in patients of the dienogest + Longidaze® combination therapy group compared with patients who received only dienogest.
Patients will assess the severity of uterine bleeding in the patient's diary using the Mansfield-Voda-Jorgensen scale.
There are five scoring options ranging from light bleeding to heavy bleeding.
The rating is determined by the frequency of changing sanitary napkins or tampons, the degree of absorption of these products with blood, and also depends on the absorption properties of these products.
|
Day 0, Day 30, Day 90, Day 150, Day 180
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 26, 2019
Primary Completion (Actual)
May 14, 2021
Study Completion (Anticipated)
August 1, 2021
Study Registration Dates
First Submitted
July 5, 2021
First Submitted That Met QC Criteria
July 5, 2021
First Posted (Actual)
July 15, 2021
Study Record Updates
Last Update Posted (Actual)
July 22, 2021
Last Update Submitted That Met QC Criteria
July 15, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISLAND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on External Genital Endometriosis
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Sydney; University of CagliariActive, not recruitingEndometriosis | Surgery | Gynecologic Disease | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis of Colon | Endometriosis of BladderBelgium, Italy, Australia
-
AbbVie (prior sponsor, Abbott)AlmedisCompleted
-
Uludag UniversityRecruitingEndometriosis | Deep Endometriosis | Endometriosis-related Pain | Endometriosis; PeritoneumTurkey
-
Universitaire Ziekenhuizen KU LeuvenSemmelweis UniversityActive, not recruitingEndometriosis | Endometriosis-related Pain | Endometriosis, Rectum | Endometriosis; BowelBelgium, Hungary
-
Chinese University of Hong KongRecruitingEndometriosis | Endometriosis Ovary | Endometriosis-related PainHong Kong
-
Ankara Etlik City HospitalActive, not recruitingRelationship Between Pan Immune Inflammatory Index and Endometriosis and Endometriosis StagesTurkey
-
McMaster UniversityEnrolling by invitationEndometriosis | Endometriosis (Diagnosis)Canada
-
University Hospital, Strasbourg, FranceCompletedEndometriosis OvaryFrance
-
Pontificia Universidad Catolica de ChileCompletedExternal Causes of Morbidity and Mortality | External Causes of Morbidity (V00-Y99)
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingEndometriosis, Rectum | Subfertility, Female | Endometriosis of ColonNetherlands
Clinical Trials on Bovhyaluronidase azoximer
-
NPO PetrovaxCompletedFibrosis | Lung Diseases, Interstitial | Lung; Disease, Interstitial, With Fibrosis | Post-Acute COVID-19 Syndrome | Lung Disease With PolymyositisRussian Federation
-
NPO PetrovaxCompletedFibroses, PulmonaryRussian Federation
-
NPO PetrovaxCompletedInfections, CoronavirusBelarus, Russian Federation
-
NPO PetrovaxActive, not recruitingInfections, CoronavirusRussian Federation, Slovakia